Aura Biosciences, Inc.
HealthcareNASDAQ:AURA · NASDAQ Global Market
+$0.20 today
Vol 0.96M · Avg 0.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-77.6%
avg -59.3%
ROIC
-73.1%
avg -58.2%
ROA
-62.7%
avg -50.6%
Analysis
ROA is currently the strongest return metric at -62.7% versus its period average of -50.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Elisabet de los Pinos | Founder, Chief Executive Officer, President & Director | $950,496.00 | — | 52 | $249,000.00 | 0.39% |
Jill Hopkins | Chief Medical Officer & President of Research and Development | $792,750.00 | — | 61 | $321,340.00 | 0.50% |
Conor Kilroy | Chief Legal Officer & Secretary | $611,162.00 | — | 44 | $217,835.00 | 0.34% |
Anthony S. Gibney | Chief Financial & Business Officer | $604,091.00 | — | 55 | $278,178.00 | 0.43% |
Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | — | — | — | $278,178.00 | 0.43% |
Mark Plavsic | Chief Technology Officer | — | — | 65 | $243,736.00 | 0.38% |
Sabine Brookman-May | Senior Vice President & Therapeutic Area Head of Urologic Oncology | — | — | — | — | — |
Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology | — | — | — | — | — |
Patrick Nealon | Senior Vice President of Clinical Development Operations | — | — | — | — | — |
Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer | — | — | 52 | $80,472.00 | 0.13% |
Natalie C. Holles | President, CEO & Director | — | — | 53 | $2.17M | 3.38% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$40.03M
Net Sentiment
$40.03M
Net selling
Most Active
Elazzouzi Amy
4 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $40.03M over the last 12 months. That adds up to net selling of $40.03M. Elazzouzi Amy was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages AURA?
Aura Biosciences, Inc. (AURA) lists 11 active executives. The top listed executive is Anthony Daniels, Vice President & Therapeutic Area of Head Ocular Oncology.
Are AURA insiders buying or selling?
Recent insider activity shows net buying of $55.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.